Laurus Labs Q4 FY25 PAT up 208% to Rs. 234 Cr

The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25

Laurus Labs posts Q3 FY25 consolidated PAT higher at Rs. 92.30 Cr

Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024

Laurus Labs invests in Laurus Bio

Laurus Labs posts Q2 FY25 consolidated PAT at Rs. 19.84 Cr

Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024

Laurus Labs inaugurates Rs. 250 crore R&D facility in Telangana

Total investment incurred for setting up the new R&D Rs 250 crore

USFDA concludes audit for Laurus Labs’ API manufacturing facility at Hyderabad with zero Form 483 observations

The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices

Laurus Labs posts Q1 FY25 consolidated PAT at Rs. 12.51 Cr

Laurus Labs has reported total income of Rs. 1,197.42 crores during the period ended June 30, 2024

Briefs: Family Care Hospitals, Laurus Labs and Bafna Pharmaceuticals

Laurus Labs receives EIR from USFDA for API facilities

Laurus Labs posts Q4 FY24 consolidated PAT at Rs. 75.61 Cr

Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024

Laurus Labs forms JV company

KRKA holds 51% and Laurus Labs holds 49% shareholding